| Alisa T Quiet, LPN | |
|
9 Walsh Ter, Jericho, VT 05465-3005 | |
| (802) 274-0971 | |
| Not Available |
| Full Name | Alisa T Quiet |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 9 Walsh Ter, Jericho, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538880059 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 025.0136275 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Alisa T Quiet, LPN 9 Walsh Ter, Jericho, VT 05465-3005 Ph: (802) 274-0971 | Alisa T Quiet, LPN 9 Walsh Ter, Jericho, VT 05465-3005 Ph: (802) 274-0971 |
News Archive
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
The loss of brain tissue, called brain atrophy, is a normal part of aging, but multiple sclerosis (MS) accelerates the process.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Centene Corporation today announced the pricing of its previously announced follow-on public offering of 5,000,000 shares of its common stock at a public offering price of $19.25 per share.
› Verified 9 days ago